Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Ann E. Emmel"'
Publikováno v:
American Journal of Clinical Oncology. 38:575-582
Objectives We sought to determine the speed at which patients were accrued into published phase III oncology trials across geographic locations and to identify the factors that may influence this process. Materials and methods We searched OVID-Medlin
Autor:
Jennifer A. Lee, Ann E. Emmel, Kaye L. Crampton, Kristina Rokkones, Eileen A. Severson, Michelle A. Mathiason, Ronald S. Go, Rasmus T. Hoeg, Stephanie L. Serck
Publikováno v:
American Journal of Clinical Oncology. 32:253-257
Objectives: Translation of evidence-based medicine into oncology practice depends on timely and full publication of clinical trials. We investigated publication outcomes of Phase II trial abstracts from the annual meetings of the American Society of
Autor:
Ann E. Emmel, Michelle A. Mathiason, Alcee J. Jumonville, Ronald S. Go, Sandra K. Wee, Nancy R. Ruther
Publikováno v:
Journal of Clinical Oncology. 30:6074-6074
6074 Background: There is a perception that patient accrual may be slower in the US than it is in Europe (Wang-Gillam A et al, J Clin Oncol 2010;28:3803-3807). However, a systematic study has not been performed. We seek to determine the speed at whic
Autor:
Lori A. Meyer, K. L. Crampton, Ronald S. Go, J. E. Schroeder, Kathleen A. Frisby, Ann E. Emmel, S. R. Pingali, C. M. Meyer, Michelle A. Mathiason, Debbie L. Sieber
Publikováno v:
Journal of Clinical Oncology. 28:6069-6069
6069 Background: Systematic analysis of trials conducted by ECOG is unavailable. Methods: From the National Cancer Institute and ECOG websites, we obtained a list of therapeutic trials conducted by...
Autor:
Alcee J. Jumonville, Ann E. Emmel, Jennifer A. Lee, Ronald S. Go, S. L. Serck, Michelle A. Mathiason, K. L. Crampton, Rasmus T. Hoeg, K. Rokkones, E. A. Severson
Publikováno v:
Journal of Clinical Oncology. 24:6010-6010
6010 Background: Translation of evidence-based medicine into clinical practice depends on timely and full publication of clinical trials. Previous studies have shown that a substantial number of phase I and III trials presented at the annual meetings